CN Patent

CN109758437A — 一种雾化吸入用尼达尼布冻干脂质体制剂及其制备方法

Assigned to Beijing Kerui Innovative Drug Research Co Ltd · Expires 2019-05-17 · 7y expired

What this patent protects

本发明公开了一种治疗肺纤维化的雾化吸入用尼达尼布冻干脂质体制剂及其制备方法，该冻干脂质体制剂单剂量中含有：10‑80mg尼达尼布或其盐(以游离尼达尼布的量计算)、25‑250mg脂质、100‑1000mg磷脂、20‑150mg等渗剂。本发明制备的该制剂稳定性好，粒径小，适用于雾化给药，同时该冻干脂质体制剂具有高效、低毒、安全度高的特点，极大地降低了患者用药的肝肾毒性。

USPTO Abstract

本发明公开了一种治疗肺纤维化的雾化吸入用尼达尼布冻干脂质体制剂及其制备方法，该冻干脂质体制剂单剂量中含有：10‑80mg尼达尼布或其盐(以游离尼达尼布的量计算)、25‑250mg脂质、100‑1000mg磷脂、20‑150mg等渗剂。本发明制备的该制剂稳定性好，粒径小，适用于雾化给药，同时该冻干脂质体制剂具有高效、低毒、安全度高的特点，极大地降低了患者用药的肝肾毒性。

Drugs covered by this patent

Patent Metadata

Patent number
CN109758437A
Jurisdiction
CN
Classification
—
Expires
2019-05-17
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Kerui Innovative Drug Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.